Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward

Giselle Sholler, Division Chief Pediatric Hematology/Oncology/BMT at Penn State Health Children’s Hospital, shared on LinkedIn:

“Our research that led to the FDA-ODAC 70% approval for moving DFMO forward had been published in the Journal of Clinical Oncology!! I am so proud of our Beat Childhood Cancer Research Consortium at Penn State College of Medicine in collaboration with US WorldMeds for this article. We are hopeful and optimistic that this research will successfully navigate the drug through the approval process!”

For the article click here.
Source: Giselle Sholler/LinkedIn